Emerging drugs for the treatment of axial spondyloarthritis
- 2 January 2018
- journal article
- review article
- Published by Taylor & Francis Ltd in Emerging Drugs
- Vol. 23 (1), 83-96
- https://doi.org/10.1080/14728214.2018.1445719
Abstract
Introduction: The treatment of axial spondyloarthritis(axSpA) has been for nearly 15 years constricted to non-steroidal antirheumatic drugs and TNFα inhibitors. With the approval of secukinumab, a drug targeting the interleukin(IL)-17 axis became available. Nonetheless, an unmet need for further emerging therapeutic options remains. Areas covered: This review summarizes the recent and ongoing clinical trials with novel drugs in axSpA. Besides secukinumab, further therapeutics directed against the IL-17A (e.g. ixekizumab) as well as the dual IL-17A and F inhibitor bimekizumab and the IL-17RA antibody brodalumab are in development. Furthermore, several drugs targeting the IL-12/-23 axis are being evaluated. Pan-JAK and JAK-1 inhibitors might offer another effective mode of action. Expert opinion: The number of treatment options in axSpA is likely to be further extended in the coming years. Data of ongoing studies are needed to prove the efficacy of drugs directed against the IL-12/-23 axis as well as of JAK inhibition, whilst targeting the IL-17 axis was shown to be as effective as TNF inhibition by indirect comparison. There is an emerging need for trials aiming at identification of optimal treatment strategies in the scope of the treat-to-target concept in axSpA.Keywords
Funding Information
- not funded
This publication has 138 references indexed in Scilit:
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsThe Lancet, 2013
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals Of The Rheumatic Diseases, 2013
- Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical TrialsOphthalmology, 2013
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Annals Of The Rheumatic Diseases, 2012
- Economic Considerations of the Treatment of Ankylosing SpondylitisThe American Journal of the Medical Sciences, 2012
- Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trialAnnals Of The Rheumatic Diseases, 2011
- Induction of Intestinal Th17 Cells by Segmented Filamentous BacteriaCell, 2009
- No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialAnnals Of The Rheumatic Diseases, 2007
- Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trialAnnals Of The Rheumatic Diseases, 2006
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984